NO20051351L - Gene therapy for critical ischemia in wild-type or mutant eNOS limbs - Google Patents

Gene therapy for critical ischemia in wild-type or mutant eNOS limbs

Info

Publication number
NO20051351L
NO20051351L NO20051351A NO20051351A NO20051351L NO 20051351 L NO20051351 L NO 20051351L NO 20051351 A NO20051351 A NO 20051351A NO 20051351 A NO20051351 A NO 20051351A NO 20051351 L NO20051351 L NO 20051351L
Authority
NO
Norway
Prior art keywords
enos
polypeptides
wild
limbs
type
Prior art date
Application number
NO20051351A
Other languages
Norwegian (no)
Inventor
Katalin Kauser
Gabor Rubanyi
William P Dole
Hu Sheng Qian
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20051351L publication Critical patent/NO20051351L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

Foreliggende oppfinnelse tilveiebringer nye fremgangsmåter for forhindring, diagnostisering og behandling av kritisk lemiskemi (CLI) ved å benytte eNOS-polypeptider og polynukleotider for å modulere eNOS-aktivitet i celler. Villtype- og mutant-eNOS-polypeptider og polynukleotider som koder for slike polypeptider blir tilveiebrakt for anvendelse i fremgangsmåter ifølge foreliggende oppfinnelse. De muterte eNOS-polypeptidene ifølge den foreliggende oppfinnelse har minst én mutasjon tilsvarende et sete i et funksjonelt domene i en pattedyr-eNOS som er fosforylert i celler.The present invention provides novel methods for preventing, diagnosing and treating critical lemma chemistry (CLI) using eNOS polypeptides and polynucleotides to modulate eNOS activity in cells. Wild type and mutant eNOS polypeptides and polynucleotides encoding such polypeptides are provided for use in methods of the present invention. The mutated eNOS polypeptides of the present invention have at least one mutation corresponding to a site in a functional domain of a mammalian eNOS phosphorylated in cells.

NO20051351A 2002-08-16 2005-03-15 Gene therapy for critical ischemia in wild-type or mutant eNOS limbs NO20051351L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363702P 2002-08-16 2002-08-16
PCT/US2003/025626 WO2004016761A2 (en) 2002-08-16 2003-08-15 Gene therapy for critical limb ischemia with wild type or mutant enos

Publications (1)

Publication Number Publication Date
NO20051351L true NO20051351L (en) 2005-04-28

Family

ID=31888259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051351A NO20051351L (en) 2002-08-16 2005-03-15 Gene therapy for critical ischemia in wild-type or mutant eNOS limbs

Country Status (15)

Country Link
US (1) US20040120930A1 (en)
EP (1) EP1536689A4 (en)
JP (1) JP2005539031A (en)
KR (1) KR20050042162A (en)
CN (2) CN101391105A (en)
AU (1) AU2003263844A1 (en)
BR (1) BR0313515A (en)
CA (1) CA2494845A1 (en)
IL (1) IL166362A0 (en)
MX (1) MXPA05001763A (en)
NO (1) NO20051351L (en)
PL (1) PL375446A1 (en)
RU (1) RU2005107414A (en)
WO (1) WO2004016761A2 (en)
ZA (1) ZA200502181B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105102623A (en) * 2013-01-30 2015-11-25 内布拉斯加大学董事会 Compositions and methods for treating complications associated with diabetes
CN109415714A (en) * 2016-04-29 2019-03-01 艾诺奥医药品有限公司 Enhance the delivering of medicament using chondroitinase and/or hyaluronidase in vivo
CN105944243A (en) * 2016-05-12 2016-09-21 段俊丽 Regulation and control device for eNOS (Endothelial nitric oxide synthase) expression and activation and treatment device for peripheral arterial diseases
CN107802826B (en) * 2017-10-26 2020-02-18 首都医科大学宣武医院 Use of eNOS mutants to promote angiogenesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506008A (en) * 1998-03-09 2002-02-26 セント エリザベス メディカル センター Compositions and methods for modulating angiogenesis
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
CA2369764A1 (en) * 1999-04-16 2000-10-26 Yale University Enos mutations useful for gene therapy and therapeutic screening

Also Published As

Publication number Publication date
CN1688197A (en) 2005-10-26
WO2004016761A3 (en) 2005-03-17
CA2494845A1 (en) 2004-02-26
CN100408101C (en) 2008-08-06
AU2003263844A1 (en) 2004-03-03
JP2005539031A (en) 2005-12-22
PL375446A1 (en) 2005-11-28
KR20050042162A (en) 2005-05-04
IL166362A0 (en) 2006-01-16
ZA200502181B (en) 2006-09-27
RU2005107414A (en) 2006-01-27
EP1536689A4 (en) 2006-09-06
WO2004016761A2 (en) 2004-02-26
BR0313515A (en) 2005-10-18
CN101391105A (en) 2009-03-25
US20040120930A1 (en) 2004-06-24
MXPA05001763A (en) 2005-08-19
EP1536689A2 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
Keller et al. Population genomic signatures of divergent adaptation, gene flow and hybrid speciation in the rapid radiation of L ake V ictoria cichlid fishes
Nyström et al. Genetic consequences of a demographic bottleneck in the Scandinavian arctic fox
Glaser et al. The ConSurf‐HSSP database: the mapping of evolutionary conservation among homologs onto PDB structures
NO20051351L (en) Gene therapy for critical ischemia in wild-type or mutant eNOS limbs
Paetkau et al. Genetic assignment methods for the direct, real‐time estimation of migration rate: a simulation‐based exploration of accuracy and power
Valente et al. DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36. 13–36.32 in an Italian family with cranial‐cervical or upper limb onset
David et al. Protein–protein interaction sites are hot spots for disease‐associated nonsynonymous SNPs
Kenkel et al. Evidence for a host role in thermotolerance divergence between populations of the mustard hill coral (P orites astreoides) from different reef environments
Evanno et al. Detecting the number of clusters of individuals using the software STRUCTURE: a simulation study
Petren et al. Comparative landscape genetics and the adaptive radiation of Darwin's finches: the role of peripheral isolation
Wen et al. Using linear predictors to impute allele frequencies from summary or pooled genotype data
Mendes et al. A multispecies coalescent model for quantitative traits
Gligor et al. Hybridization between mouse lemurs in an ecological transition zone in southern Madagascar
Tang et al. Joint testing of genotype and ancestry association in admixed families
Suzuki Cellular mechanisms of myogenic activity in gastric smooth muscle
Poustka et al. On the origin of the chordate central nervous system: expression of onecut in the sea urchin embryo
DK1590467T3 (en) Use of regulatory sequences for specific transient expression in neuronally determined cells
de Gruijter et al. Contrasting signals of positive selection in genes involved in human skin-color variation from tests based on SNP scans and resequencing
Shohat et al. Convergence and divergence in the genetics of psychiatric disorders from pathways to developmental stages
Sadrieh et al. Quantifying the origins of population variability in cardiac electrical activity through sensitivity analysis of the electrocardiogram
Thompson et al. Rapid evolution of a voltage-gated sodium channel gene in a lineage of electric fish leads to a persistent sodium current
Sy et al. Detection of kdr and ace-1 mutations in wild populations of Anopheles arabiensis and An. melas in a residual malaria transmission area of Senegal
Burns Deactivation mechanisms of rod phototransduction: the Cogan lecture
Mao et al. Whole‐genome SNP data unravel population structure and signatures of selection for black plumage of indigenous chicken breeds from Jiangxi province, China
Jons et al. Mutations in Conserved Amino Acids in the KCNQ1 Channel and Risk of Cardiac Events in Type‐1 Long‐QT Syndrome

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application